Kuros BiosciencesCSBTF 71 Quick Ratio is 1.45 as of Dec. 2025, which is 56% below its 10-year median of 3.26. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Kuros Biosciences ranks worse than 61.94% on this metric.
Kuros Biosciences has a quick ratio of 1.45. It generally indicates good short-term financial strength.
The historical rank and industry rank for Kuros Biosciences's Quick Ratio or its related term are showing as below:
CSBTF'
s Quick Ratio Range Over the Past 10 Years
Min: 1.45 Med: 3.26 Max: 8.39
Current: 1.45
During the past 13 years, Kuros Biosciences's highest Quick Ratio was 8.39. The lowest was 1.45. And the median was 3.26.
CSBTF's Quick Ratio is ranked worse than 61.94% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.865
vs CSBTF: 1.45
Kuros Biosciences (OTCPK:CSBTF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Kuros Biosciences Quick Ratio Related Terms
Kuros Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Kuros Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Kuros Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Kuros Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (CSBTF) has a Quick Ratio of 1.45 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Kuros Biosciences and its competitors. This is 56% below median its historical median of 3.26. Over the past decade, Kuros Biosciences' Quick Ratio has ranged from 1.45 to 8.39. According to the industry distribution chart, Kuros Biosciences ranks #529 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 61.9%.
Is Kuros Biosciences' Quick Ratio too high?
Kuros Biosciences' current Quick Ratio of 1.45 is 56% below median its 10-year median of 3.26. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 8.39. The Medical Devices & Instruments industry median Quick Ratio is 1.87. Kuros Biosciences' value of 1.45 is 22.3% below this industry median. Based on the distribution chart, Kuros Biosciences ranks #529 out of 854 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #529 out of 854 companies for Quick Ratio. This places Kuros Biosciences in the lower half of its industry. The industry median Quick Ratio is 1.87. Kuros Biosciences' value of 1.45 is 22.3% below this benchmark. Historically, Kuros Biosciences' own Quick Ratio has ranged from 1.45 to 8.39 over the past decade. While the company's 10-year median is 3.26 vs. the industry median of 1.87, Kuros Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.87, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuros Biosciences's current Quick Ratio of 1.45 is 22.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Kuros Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuros Biosciences's current Quick Ratio is 1.45, which is 56% below median its own 10-year median of 3.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current Quick Ratio is 1.45, which is 56% below median its 10-year median of 3.26 and 22.3% below the Medical Devices & Instruments industry median of 1.87. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Quick Ratio is 1.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuros Biosciences (CSBTF) Overvalued in 2026?
Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued.
The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72.
GuruFocus considers Kuros Biosciences to be Significantly Undervalued.
Key valuation signals for CSBTF:
Quick Ratio: 1.45 (56% below median its 10-year median of 3.26)
GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
Industry Position: 22.3% below the Medical Devices & Instruments median (#529 of 854)
No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score
Get the complete analysis for CSBTF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBTF has been successfully added to your 
